<DOC>
	<DOCNO>NCT01437709</DOCNO>
	<brief_summary>This study do understand treat Mantle Cell Lymphoma ( MCL ) . The goal treatment control lymphoma least amount side effect . In many case , MCL treat antibody plus chemotherapy . An antibody laboratory-produced substance create attach protein cancer cell , eventually destroy . Chemotherapy medicine specifically destroy cancer cell . The purpose study find effect , good and/or bad , drug Ofatumumab Bendamustine type cancer . Patients study either receive Ofatumumab alone , Ofatumumab combine Bendamustine .</brief_summary>
	<brief_title>Ofatumumab With Without Bendamustine Patients With Mantle Cell Lymphoma Ineligible Autologous Stem Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Untreated , nontransplant eligible , newly diagnose mantle cell lymphoma measurable disease determine CT , bone marrow biopsy . Age &gt; = 65 year &gt; 18 year ineligible HDT/ASCT . Subjects must candidate intensive highdose chemotherapy , without autologous stem cell transplant ( ASCT ) , due one follow factor : Age ≥ 65 year Patients &lt; 65 year age must ineligible HDT/ASCT basis comorbidity , organ dysfunction patient refusal HDT/ASCT Comorbid disease , CAD , CHF , pulmonary dysfunction , liver kidney dysfunction , preclude high dose therapy secondary expect increased morbidity mortality . poor performance status ( KPS 70 % less ) Ejection fraction &lt; 45 % Impaired pulmonary function test DLCO &lt; 50 % expect Patient refusal Medical condition opinion treat physician DMT preclude HDT/ASCT . Patients must serum creatinine clearance ≥ 40 mL/min ( per Jelliffe method ) 12hour 24hour urine creatinine clearance . Patients must ANC &gt; 1,000/mcl Platelets &gt; 100,000/mcl ( unless secondary MCL ) . Patients must bilirubin level &lt; 2.0 mg/dl absence history Gilbert 's disease ( pattern consistent Gilbert 's ) . Negative serology Hepatitis B ( HB ) define negative test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HB DNA test perform negative , patient may include must undergo HBV DNA PCR test begin treatment throughout treatment duration , least every 2 month . In addition patient require treatment Entacavir .5mg po qday per MSKCC institutional guideline . No active comorbid cardiac condition active CHF CAD . KPS performance ≥ 70 % . Histologically confirm mantle cell lymphoma classify accord WHO criterion confirm MSKCC . No prior treatment mantle cell lymphoma exception corticosteroid 7 day less 1 course involvedfield radiation . No prior malignancy within 5 yr , unless treat early stage breast cancer , treat carcinoma situ cervix , resect skin malignancy , treated prostate cancer . Women premenopausal must negative serum pregnancy test . Subjects must agree use appropriate contraception 4 week completion chemotherapy . Patients must HIV negative , negative serology Hepatitis C. Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , hepatic involvement MCL , stable chronic liver disease per investigator assessment ) . Known pregnancy breastfeed . Medical illness unrelated MCL within prior one month preclude administration chemotherapy safely . This include patient uncontrolled infection , chronic renal insufficiency , myocardial infarction within past 6 month , unstable angina , active congestive heart failure , cardiac arrhythmia chronic atrial fibrillation chronic active persistent hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bendamustine HCL</keyword>
	<keyword>Ofatumumab ( GSK 1841157 )</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Chemoimmunotherapy</keyword>
	<keyword>11-050</keyword>
</DOC>